Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (211-220 of 442) with videos related to

Pageof 45
Sort By:
JCO Precision Oncology|July 21, 2022
Identification of <i>KRAS</i><sup></sup> Mutations in Circulating Tumor DNA in Patients With CancerKyaw Z Thein, Amadeo B Biter, Kimberly C Banks, et al.
The Oncologist|March 17, 2021
Overview of Ocular Side Effects of SelinexorNagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
Cancer Genetics|December 20, 2021
Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinibErin R Rudzinski, Jaclyn Hechtman, Sinchita Roy-Chowdhuri, et al.
Molecular Cancer Therapeutics|December 17, 2010
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancerApostolia-Maria Tsimberidou, Wallace Akerley, Matthias C Schabel, et al.
The Oncologist|October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unitSiqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Journal for Immunotherapy of Cancer|October 9, 2024
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignanciesJoe Y Chang, Xinyan Xu, Girish S Shroff, et al.
Oncotarget|July 9, 2014
Characteristics and survival of patients with advanced cancer and p53 mutationsRabih Said, Yang Ye, David S Hong, et al.
Oncotarget|May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapyRabin Said, David S Hong, Carla L Warneke, et al.
Investigational New Drugs|April 26, 2014
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapyMehmet Asim Bilen, Jean-Bernard Durand, Lacey McQuinn, et al.
Pageof 45

Showing results (211-220 of 442) with videos related to

Sort By:
Pageof 45
JCO Precision Oncology|July 21, 2022
Identification of <i>KRAS</i><sup></sup> Mutations in Circulating Tumor DNA in Patients With CancerKyaw Z Thein, Amadeo B Biter, Kimberly C Banks, et al.
The Oncologist|March 17, 2021
Overview of Ocular Side Effects of SelinexorNagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
Cancer Genetics|December 20, 2021
Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinibErin R Rudzinski, Jaclyn Hechtman, Sinchita Roy-Chowdhuri, et al.
Molecular Cancer Therapeutics|December 17, 2010
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancerApostolia-Maria Tsimberidou, Wallace Akerley, Matthias C Schabel, et al.
The Oncologist|October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unitSiqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Journal for Immunotherapy of Cancer|October 9, 2024
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignanciesJoe Y Chang, Xinyan Xu, Girish S Shroff, et al.
Oncotarget|July 9, 2014
Characteristics and survival of patients with advanced cancer and p53 mutationsRabih Said, Yang Ye, David S Hong, et al.
Oncotarget|May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapyRabin Said, David S Hong, Carla L Warneke, et al.
Investigational New Drugs|April 26, 2014
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapyMehmet Asim Bilen, Jean-Bernard Durand, Lacey McQuinn, et al.
Pageof 45